Cynata Therapeutics Ltd V.CYP

Primary Symbol: CYYNF

Healthcare Biotechnology

Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and regenerative medicine company. The Company is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells and a precursor cell, mesenchymoangioblast (MCA) to manufacture cell therapy products, including mesenchymal stem cells, on a commercial scale. Its lead product candidate, CYP-001, is under Phase I trial and developed for the treatment of steroid-resistant acute graft-versus-host disease (GvHD). Clinical trials of Cymerus products in osteoarthritis, which is under Phase III trial, and diabetic foot ulcers (DFU) are ongoing. In addition, the Company has demonstrated the utility of its Cymerus technology in preclinical models of various diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome and other.

OTCPK:CYYNF - Post by User

Cynata Therapeutics Ltd

Bullboard Posts

Post by GarryJan1on Dec 22, 2018 3:29pm

127 Views

Post# 29150694

Barchart sill in the sell mode. I guess the

tax selling and lower interest in lithium stocks this year has cause the slump. Then there is still the lithium from clays negative mind set caused by hectorite clays. Yet Bacanora is going to produce lithium in small batches by roasting in lilns at around 1000 % in Mexico. Go figure ?

The good Dr Willoughby will have to prove conclusively the Cypress can produce battery grade lithium form our clays.

https://www.barchart.com/stocks/quotes/CYP.VN/opinion

Bullboard Posts

Investing in Canada's lumber market